HK Stock Market Move | 3SBIO (01530) rose more than 4%, gaining commercialization rights for multiple indications of the HER2 ADC drug DB-1303 developed by Immutep Biopharma.
Sanbio (01530) rose more than 4%, as of the time of writing, it increased by 4.01%, reporting HKD 5.96, with a turnover of HKD 47.4687 million.
3SBIO (01530) rose over 4%, at the time of release, it was up by 4.01% at 5.96 Hong Kong dollars, with a transaction value of 47.4687 million Hong Kong dollars.
On the news front, recently, 3SBIO's subsidiary Shenyang 3SBIO Co., Ltd. (referred to as 3SBIO) and IME Bio-Tech (Shanghai) Co., Ltd. (referred to as IME Bio-Tech) jointly announced that they have signed a cooperation agreement on the HER2 ADC drug DB-1303. According to the agreement, 3SBIO will obtain the commercialization rights of IME Bio-Tech's HER2 ADC drug DB-1303 for multiple indications in Mainland China, Hong Kong, and Macau. IME Bio-Tech will receive an initial payment as well as corresponding research and development and sales milestone payments. At the same time, IME Bio-Tech will continue to be responsible for clinical development and registration of related indications in the cooperation area.
Related Articles

PLATEAU TL (08402) announced its annual performance with a net loss of 3.6579 million Singapore dollars for shareholders, an increase of 237.45% from the previous year.

GLORY FLAME (08059) released its annual performance report, reporting a net loss of HKD 15.409 million for shareholders, a 24.22% increase compared to the previous year.

GUDOU HLDGS (08308) released its annual performance, with a net loss attributable to shareholders of 61.932 million yuan, an increase of 21.89% year-on-year.
PLATEAU TL (08402) announced its annual performance with a net loss of 3.6579 million Singapore dollars for shareholders, an increase of 237.45% from the previous year.

GLORY FLAME (08059) released its annual performance report, reporting a net loss of HKD 15.409 million for shareholders, a 24.22% increase compared to the previous year.

GUDOU HLDGS (08308) released its annual performance, with a net loss attributable to shareholders of 61.932 million yuan, an increase of 21.89% year-on-year.

RECOMMEND

Chinese Innovative Drug Assets Attract Major Foreign Acquisition, Cooperation Models Diversify
26/03/2026

Four Giants Subscribe As Memory Manufacturer Confirms TWD 78.718 Billion Private Placement For Capacity Expansion
26/03/2026

Year‑On‑Year Surge Exceeding 500%: Hong Kong IPOs Top HKD 100 Billion This Year
26/03/2026


